Two-Drug combo aims to shrink upper tract bladder cancer before surgery

NCT ID NCT06356155

Recruiting now Disease control Sponsor: University of Michigan Rogel Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This trial tests whether giving two drugs—enfortumab vedotin and pembrolizumab—before surgery can improve outcomes for people with upper tract urothelial cancer (a type of bladder cancer in the kidney or ureter). Participants receive the drugs intravenously, then undergo surgery to remove the tumor, followed by more pembrolizumab. The study measures how many patients have a significant tumor response after the drug combination.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: enfortumab vedotin and pembrolizumab
What this could lead to: If successful, this combination could become a new pre-surgery treatment option for upper tract urothelial cancer, potentially improving outcomes.
What could go wrong: This is an early-phase, single-arm trial with only 32 participants. The combination may not prove more effective than standard care and could cause side effects like nerve damage or immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UPPER TRACT UROTHELIAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

renal pelvis/ureter urothelial carcinoma transitional cell carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UROTHELIAL CARCINOMA

Contacts and locations

Locations

Fox Chase Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19111, United States
University of Michigan Comprehensive Cancer Center
RECRUITING

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.